Phase II Trial of Oral Vinorelbine in Children With Recurrent or Progressive Unresectable Low-Grade Glioma
The purpose of this study is to determine whether oral vinorelbine is effective in the treatment of children with progressive or recurrent unresectable low grade glioma.
Low-Grade Glioma
DRUG: ORAL VINORELBINE
Progression free survival, no progressive disease according to RANO criteria, 9 months
Response rate, Complete, partial and minor responses according to RANO criteria, 6 months|Response rate, Complete, partial and minor responses according to RANO criteria, 12 months|Progression Free Survival PFS, No progressive disease according to RANO criteria, 36 months|Overall Survival OS, Death incidence, 36 months|Growth Modulation Index GMI, GMI defined as PFS2/ PSF1 ratio (PFS2 = PFS since the beginning of study treatment ; PFS1 = PFS observed in previous line of treatment), 36 months|Adverse events, According to NCI-CTC AE scale v4.0, 12 months|Modifications of tumor aspects in diffusion and perfusion MRI, Cerebral and/or spinal MRI (morphological and functional) with 2 dimensional assessment of target lesions., At each tumor assessment, after 3, 6, 9 and 12 cycles of treatment, at the end of study, then every 4 months during the first year post therapy, then every 6 months for 3 years, if no prior progressive disease|Constitutional polymorphisms of cyp3A5, ABCB1, Single nucleotide polymorphisms (SNPs) will be analyzed by real time PCR and correlated with efficacy and toxicity of vinorelbine, Before the start of treatment|Pharmacokinetic, Plasmatic concentrations measured by LC-MS/MS (liquid chromatography tandem mass spectrometry) ; Area under the curve (AUC), maximal concentration (Cmax), time to Cmax (Tmax)., cycles 1 and 2, prior to the initial dose, 30 min, 1, 1.5, 2, 3, 6, 8, 10 and 26 hours post-dose|Medical costs, Costs of medical care including : hospitalisations, emergency admissions, nursing care at home, medical consultations, diet support..., during all the study (up to 1 year)|Health Utilities Index (HUI), Health Utilities Index (HUI), Before the treatment, then at day 1 of 1st cycle, after the 3th, 6th, 9th and the 12th cycles of study treatment, and at the end of study (up to 1 year)
The aim of this study is to determine efficacy of oral vinorelbine in children with progressive or recurrent unresectable low grade glioma, in addition to safety, pharmacokinetic, pharmacogenetic, medical costs and quality of life.